US House Commerce Committee bill for FDA reform due this month:
This article was originally published in Clinica
The US House Commerce Committee is expected to introduce its FDA reform bill this month. In support of Tom Bliley's "comprehensive package" of reforms, House Republicans have requested the legislation be given priority this year, says industry association HIMA. The budgetary problems could jeopardise FDA reform legislation, warns HIMA, since if this controversial issue is not discussed soon it is unlikely to be taken up as the 1996 election approaches. A hearing on Senator Nancy Kassebaum's bill has been set for February 21st-22nd.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.